Volume 3, Issue 1, March 2019, Page: 6-9
The Short-Term and Long-Term Effects of Cardiac Resynchronization Therapy in Heart Failure Patients
Xuefang Zhang, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Ying Qin, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Gaoxing Zhang, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Weidong Gao, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Yucheng Peng, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Qiang Ren, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Gang Sun, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Jinxue Liu, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Bin Zhang, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Juan Wu, Department of Cardiology, Jiangmen Central Hospital, Affiliated to Sun Yat-Sen University, Jiangmen, China
Received: Dec. 14, 2018;       Accepted: Jan. 11, 2019;       Published: Feb. 19, 2019
DOI: 10.11648/j.ccr.20190301.12      View  255      Downloads  43
Abstract
Objective to evaluate the short-term and long-term effects of cardiac resynchronization therapy in heart failure patients. Methods We continuous assessed forty-eight heart failure patients who underwent CRT implantation in our hospital from January 2008 to December 2012, evaluate/measure NYHA grade, left ventricular diastolic diameter (LVEDd), left ventricular ejection fraction (LVEF) and B-type natriuretic peptides (BNP) before cardiac resynchronization therapy and half year, one year, two years after cardiac resynchronization therapy. Results Compared to the results before cardiac resynchronization, half year, one year and two years later, NYHA grade, LVEF, LVEDd, BNP improved significantly (P <0.05); Compared to the results of half year after cardiac resynchronization therapy, one year and two years later, NYHA grade, LVEF, LVEDd, BNP also improved significantly (P<0.05); However, compared the results between one year and two years later after cardiac resynchronization therapy, there were no difference as to NYHA grade, LVEF, LVEDd and BNP (P>0.05). Conclusions CRT could improve cardiac function in patients with congestive heart failure, however, when we followed up the patients for two years, cardiac function did not improve further.
Keywords
Cardiac Resynchronization Therapy, Cardiac Function, B-Type Natriuretic Peptides
To cite this article
Xuefang Zhang, Ying Qin, Gaoxing Zhang, Weidong Gao, Yucheng Peng, Qiang Ren, Gang Sun, Jinxue Liu, Bin Zhang, Juan Wu, The Short-Term and Long-Term Effects of Cardiac Resynchronization Therapy in Heart Failure Patients, Cardiology and Cardiovascular Research. Vol. 3, No. 1, 2019, pp. 6-9. doi: 10.11648/j.ccr.20190301.12
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. N Engl J Med, 2009, 361 (14):1329-1338.
[2]
Ruwald MH, Solomon SD, Foster E, et al. Left Ventricular Ejection Fraction Normalization in Cardiac Resynchronization Therapy and Risk of Ventricular Arrhythmias and Clinical Outcomes: Results from the MADIT-CRT Trial. Circulation, 2014, 2278-2287.
[3]
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-Resynchronization Therapy with or without an Implantable Defi brillator in Advanced Chronic Heart Failure. N Engl J Med, 2004, 350 (21):2140-2150.
[4]
Cappola TP, Harsh MR, Jessup M, et al. Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and gender. J Card Fail, 2006, 12:182-188.
[5]
Castellant P, Fatemi M, Orhan E, Etienne Y, Blanc JJ. Patients with non-ischaemic dilated cardiomyopathy and hyper-responders to cardiac resynchronization therapy: characteristics and long-term evolution. Europace, 2009, 11:350-5.
[6]
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 2015, 28:1-39.
[7]
Shiller NB, Shah PM, Crawford M, et al. American Society of Echocardiography committee on standards, Subcommittee on quantitation of Two-Dimensional Echocardiograms: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr, 1989, 2:358-367.
[8]
Dong YX, Powell BD, Asirvatham SJ, Friedman PA, Rea RF, Webster TL, Brooke KL, Hodge DO, Wiste HJ, Yang YZ, Hayes DL, Cha YM. Left ventricular lead position for cardiac resynchronization: a comprehensive cinegraphic, echocardiographic, clinical, and survival analysis. Europace, 2012, 14:1139-1147.
[9]
Khand A, Gemmel I, Clark AL, et al. Is the prognosis of heart failure improving?. J Am Coll Cardiol, 2000, 36 (7):2284-2286.
[10]
Cleland JGF, Clark AL. Delivering the cumulative benefi ts of triple therapy to improve outcomes in heart failure: too many cooks will spoil the broth. J Am Coll Cardiol, 2003, 42 (7):1234-1237.
[11]
Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med, 2005, 352 (12):1539-1549.
[12]
St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation, 2003, 107:1985-1990.
[13]
Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol, 2006, 48:734-43.
[14]
Aranda JM Jr, Woo GW, Conti JB, et al. Use of cardiac resynchronization therapy to optimize betablocker therapy in patients with heart failure and prolonged QRS duration. Am J Cardiol, 2005, 95 (7):889-891.
[15]
Muraoka H, Imamura T, Kinugawa K. Reverse remodeling achieved by combination therapy with high-dose beta blocker and cardiac resynchronization. Int Heart J, 2015, 56: 462-465.
[16]
Oremus M, Don-Wauchope A, McKelvie R, Santaguida PL, Hill S, Balion C, et al. BNP and NT-proBNP as prognostic markers in persons with chronic stable heart failure. Heart Fail Rev, 2014, 19 (4):471–505.
[17]
Santaguida PL, Don-Wauchope AC, Oremus M, McKelvie R, Ali U, Hill SA, et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev, 2014, 19 (4):453–70.
[18]
Bakos Z, Chatterjee NC, Reitan C, Singh J P, Borgquist R. Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score. BMC Cardiovascular Disorders, 2018, 18:70.
Browse journals by subject